DBV Technologies (NASDAQ:DBVT) Stock Price Passes Above Fifty Day Moving Average - Here's Why

Shares of DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $8.89 and traded as high as $9.62. DBV Technologies shares last traded at $9.10, with a volume of 13,611 shares changing hands.

Analyst Ratings Changes

Several research firms recently issued reports on DBVT. JMP Securities raised their price target on DBV Technologies from $15.00 to $21.00 and gave the stock a "market outperform" rating in a research report on Tuesday, May 27th. Wall Street Zen upgraded shares of DBV Technologies from a "sell" rating to a "hold" rating in a report on Friday, May 9th. Citigroup reaffirmed an "outperform" rating on shares of DBV Technologies in a research note on Tuesday, May 27th. HC Wainwright increased their price target on shares of DBV Technologies from $7.00 to $16.00 and gave the company a "buy" rating in a research report on Monday, May 5th. Finally, The Goldman Sachs Group raised shares of DBV Technologies to a "sell" rating and set a $7.25 price target on the stock in a report on Thursday, May 29th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, DBV Technologies currently has an average rating of "Hold" and a consensus price target of $14.75.

DBV Technologies Stock Performance

The stock has a market capitalization of $259.38 million, a P/E ratio of -1.92 and a beta of -0.63. The stock has a 50-day moving average price of $8.99 and a two-hundred day moving average price of $6.00.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last posted its quarterly earnings data on Friday, April 11th. The company reported ($1.10) earnings per share (EPS) for the quarter. DBV Technologies had a negative return on equity of 278.24% and a negative net margin of 3,249.99%. The firm had revenue of $0.51 million during the quarter. Equities analysts anticipate that DBV Technologies S.A. will post -7.05 earnings per share for the current fiscal year.

Institutional Investors Weigh In On DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC bought a new position in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned approximately 0.24% of DBV Technologies at the end of the most recent quarter. 71.74% of the stock is owned by institutional investors and hedge funds.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.